E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
- To assess the efficacy of baloxavir marboxil 2% granules in otherwise healthy pediatric subjects weighing less than 20 kg with influenza virus infection.
- To assess the safety and tolerability of a single dose of baloxavir marboxil 2% granules in pediatric patients weighing less than 20 kg.
-To assess the pharmacokinetics (PK) of S-033447, the active form of S-033188 (baloxavir marboxil), after single dose administration of baloxavir marboxil 2% granules in pediatric patients weighing less than 20 kg.
|
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Male or female patients whose body weight at Screening is less than 20 kg and aged less than 12 years when informed consent obtained from the patient’s parent/legally acceptable representative and/or informed assent obtained, as appropriate to the age of patient. If the patient is younger than 1 year of age, he/she had to have body weight no less than 2500 g at birth.
- Patients with a diagnosis of influenza virus infection confirmed by all of the following: fever =/> 38 C (axillary temperature) at Screening visit and positive rapid influenza diagnostic test (RIDT) by nasopharyngeal (if difficult, nasal or throat) swabs.
- Patients with onset of symptoms within 48 hours at the time of informed consent.
|
|
E.4 | Principal exclusion criteria |
- Patients with severe symptoms of influenza virus infection requiring inpatient treatment.
- Patients with any of the following high risk factors: chronic respiratory diseases, neurological and neurodevelopmental disorders, heart disease, blood disorders, endocrine disorders, kidney disorders, liver disorders, metabolic disorders, compromised immune system.
- Patients with any disturbance of consciousness, abnormal behavior or convulsions at Screening, or with a current condition of encephalitis or encephalopathy.
- Patients with history of encephalitis, encephalopathy, epilepsy, or influenza virus infection associated abnormal behavior within the past 2 years.
- Patients with concurrent infections requiring systemic antimicrobial and/or antiviral therapy at Screening.
- Patients who have received baloxavir marboxil (Xofluza®), peramivir (Rapiacta®), laninamivir (Inavir®), oseltamivir (Tamiflu®), zanamivir (Relenza®) or amantadine (Symmetrel®) within 30 days prior to Screening (including prophylaxis).
- Patient with known allergy and/or history of significant intolerance against baloxavir marboxil and/or acetaminophen.
- Patients with severe underlying diseases.
- Patients who have been exposed to an investigational drug within 30 days or 5 half-lives of the drug prior to Screening.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Time to alleviation of influenza illness |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
1) Influenza virus titer
2) Amount of virus RNA (reverse transcription polymerase chain reaction [RT-PCR])
3) Change from baseline in influenza virus titer
4) Change from baseline in the amount of virus RNA (RT-PCR)
5) Percentage of participants positive for influenza virus titer
6) Percentage of participants positive by RT-PCR
7) Area under the curve in virus titer
8) Area under the curve in the amount of virus RNA (RT-PCR)
9) Time to cessation of viral shedding by virus titer
10) Time to cessation of viral shedding by RT-PCR
11) Time to resolution of fever
12) Percentage of participants reporting normal temperature
13) Body temperature
14) Time to alleviation of individual symptoms
15) Time to resumption of normal activity
16) Percentage of participants of influenza-related complications
17) Percentage of participants of influenza-related complications particularly seen in pediatric patients
18) Plasma concentrations of S-033447
19) Percentage of participants with adverse events
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1-6) Predose on Day 1, Days 2, 3, 4 (one visit on either Day 3 or Day 4 is mandatory), 6, 9; if flu symptoms persist: on Days 15, 22
7-10) Day 1 up to Day 22
11) Day 1 up to Day 14
12-13) Predose on Day 1 up to Day 14
14-15) Day 1 up to Day 14
16-17) Predose on Day 1 up to Day 22
18) 0.5 to 2 hours postdose on Day 1, Day 2, at one time point during the period from Day 6 to 22, and at Day 3 and/or Day 4 as needed
19) Day 1 up to Day 22
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 4 |